Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers

ICOS Controls the Pool Size of Effector-Memory and Regulatory T Cells

(2014) Y. Burmeister et al.   JOURNAL OF IMMUNOLOGY

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Ipilimumab: controversies in its development, utility and autoimmune adverse events

(2009) Jeffrey Weber   CANCER IMMUNOLOGY IMMUNOTHERAPY

Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF

(2009) L. Fong et al.   CANCER RESEARCH

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

(2009) A. Ribas et al.   CLINICAL CANCER RESEARCH

Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B

(2009) A. Paschen et al.   CLINICAL CANCER RESEARCH

Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4

(2009) O. Klein et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management

(2009) Sujana Movva et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade

(2009) Willemijn B. Breunis et al.   JOURNAL OF IMMUNOTHERAPY

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

(2009) Erika von Euw et al.   Journal of Translational Medicine

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

(2008) B. Kavanagh et al.   BLOOD

Tumor-specific Th17-polarized cells eradicate large established melanoma

(2008) P. Muranski et al.   BLOOD

CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?

(2008) C. Menard et al.   CLINICAL CANCER RESEARCH

Polyfunctional T cell responses are a hallmark of HIV-2 infection

(2008) Melody G. Duvall et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination

(2008) Hisashi Wada et al.   INTERNATIONAL JOURNAL OF CANCER

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

(2008) Lawrence Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays

(2008) Sacha Gnjatic et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

(2008) Begoña Comin-Anduix et al.   Journal of Translational Medicine

Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma

(2008) Miguel-Angel Perales et al.   MOLECULAR THERAPY

Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)

(2008) A. Ribas   ONCOLOGIST

The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation

(2008) J. D. Wolchok et al.   ONCOLOGIST

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

(2008) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE